Minerva Neurosciences (NasdaqCM:NERV) Update / briefing Transcript

Summary of Minerva Neurosciences Conference Call Company Overview - Company: Minerva Neurosciences (NasdaqCM:NERV) - Focus: Development of roluperidone for treating negative symptoms in schizophrenia Key Points Discussed Industry Context - Schizophrenia: Affects approximately 83 million people globally, with about 3.4 million in the U.S. alone [doc id='13'][doc id='14'] - Financial Burden: Estimated at $34 billion annually in the U.S., making it a leading cause of functional disability [doc id='14'] - Negative Symptoms: These symptoms significantly impair social and occupational functioning, leading to poor quality of life [doc id='14'][doc id='18'] Roluperidone Development - Unmet Need: There is currently no FDA-approved treatment specifically for negative symptoms of schizophrenia, highlighting a significant treatment gap [doc id='19'] - Clinical Trials: Roluperidone is positioned as potentially the first effective treatment for negative symptoms, with ongoing Phase III trials [doc id='2'][doc id='5'] FDA Engagement - Collaboration: Minerva has had productive discussions with the FDA regarding the design of the Phase III trial, including the use of monotherapy for roluperidone [doc id='5'][doc id='10'] - Study Design: The trial will compare roluperidone monotherapy against standard antipsychotic care, focusing on both efficacy and safety [doc id='60'] Clinical Insights - Negative Symptoms Definition: Negative symptoms include avolition, asociality, anhedonia, blunted affect, and alogia, which are minimally responsive to current treatments [doc id='20'][doc id='24'] - Avolition: Identified as a central domain affecting other negative symptoms, with evidence suggesting that improving motivation can lead to broader improvements in negative symptoms [doc id='25'][doc id='30'] Trial Results and Efficacy - Phase IIb Results: Roluperidone showed significant effects on negative symptoms, particularly at the 64 mg dose, which was associated with a large effect size [doc id='48'] - Functionality Improvement: The Personal and Social Performance Scale (PSP) indicated improvements in functioning, although effect sizes were modest [doc id='49][doc id='50'] Future Directions - Phase III Confirmatory Trial: The trial will include a screening period to ensure the right patient population, focusing on those with stable positive and negative symptoms [doc id='56][doc id='58] - Site Selection: Emphasis on quality performance metrics and minimizing variability by limiting the number of clinical sites involved [doc id='65][doc id='68] Conclusion - Overall Impact: Roluperidone has demonstrated statistical significance in improving primary negative symptoms without exacerbating positive symptoms or causing significant side effects, marking a potential breakthrough in schizophrenia treatment [doc id='53][doc id='54]